Elo Mutual Pension Insurance Co Makes New Investment in Exelixis, Inc. (NASDAQ:EXEL)

Elo Mutual Pension Insurance Co purchased a new stake in shares of Exelixis, Inc. (NASDAQ:EXEL) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 18,198 shares of the biotechnology company’s stock, valued at approximately $606,000.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Meiji Yasuda Asset Management Co Ltd. bought a new position in shares of Exelixis in the fourth quarter valued at approximately $234,000. Prudential Financial Inc. boosted its stake in Exelixis by 479.0% during the 4th quarter. Prudential Financial Inc. now owns 113,965 shares of the biotechnology company’s stock valued at $3,926,000 after purchasing an additional 94,283 shares in the last quarter. Crowley Wealth Management Inc. acquired a new position in shares of Exelixis during the 4th quarter valued at $50,000. Vanguard Group Inc. raised its stake in shares of Exelixis by 0.4% in the 4th quarter. Vanguard Group Inc. now owns 29,429,252 shares of the biotechnology company’s stock worth $979,994,000 after buying an additional 121,750 shares in the last quarter. Finally, LPL Financial LLC lifted its holdings in shares of Exelixis by 26.4% in the fourth quarter. LPL Financial LLC now owns 107,212 shares of the biotechnology company’s stock valued at $3,570,000 after buying an additional 22,370 shares during the period. 85.27% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other Exelixis news, CFO Christopher J. Senner sold 29,314 shares of the business’s stock in a transaction dated Monday, February 24th. The stock was sold at an average price of $36.14, for a total value of $1,059,407.96. Following the completion of the sale, the chief financial officer now owns 779,607 shares of the company’s stock, valued at $28,174,996.98. The trade was a 3.62 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Bob Oliver sold 18,647 shares of the firm’s stock in a transaction that occurred on Tuesday, February 25th. The shares were sold at an average price of $37.25, for a total value of $694,600.75. Following the completion of the transaction, the director now directly owns 33,514 shares in the company, valued at $1,248,396.50. The trade was a 35.75 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 140,343 shares of company stock worth $5,177,234 in the last three months. 2.85% of the stock is owned by insiders.

Exelixis Stock Down 0.4 %

EXEL stock opened at $36.70 on Monday. The company has a 50 day moving average of $35.71 and a two-hundred day moving average of $33.32. Exelixis, Inc. has a 12-month low of $20.14 and a 12-month high of $40.02. The company has a market cap of $10.27 billion, a price-to-earnings ratio of 20.73, a PEG ratio of 1.13 and a beta of 0.57.

Exelixis (NASDAQ:EXEL) last announced its quarterly earnings data on Tuesday, February 11th. The biotechnology company reported $0.48 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.51 by ($0.03). Exelixis had a return on equity of 23.52% and a net margin of 24.04%. On average, research analysts anticipate that Exelixis, Inc. will post 2.04 EPS for the current year.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on EXEL shares. BMO Capital Markets lowered shares of Exelixis from an “outperform” rating to a “market perform” rating and raised their price objective for the company from $36.00 to $40.00 in a research report on Friday, December 20th. Morgan Stanley upgraded shares of Exelixis from an “equal weight” rating to an “overweight” rating and raised their target price for the stock from $30.00 to $40.00 in a report on Monday, January 27th. Bank of America downgraded Exelixis from a “buy” rating to a “neutral” rating and increased their price objective for the company from $35.00 to $39.00 in a research report on Tuesday, December 17th. Brookline Capital Management assumed coverage on Exelixis in a report on Monday, December 23rd. They issued a “buy” rating on the stock. Finally, Oppenheimer downgraded Exelixis from an “outperform” rating to a “market perform” rating and reduced their target price for the company from $41.00 to $33.00 in a report on Friday, January 24th. One analyst has rated the stock with a sell rating, eight have assigned a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, Exelixis currently has an average rating of “Moderate Buy” and an average price target of $37.59.

Exelixis Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.